Health Care · Pharmaceutical Preparations · Nasdaq · CIK 791908 · FYE Dec 31 · Prices AT CLOSE 2026-07-21 (USD) — end-of-day, never a live or intraday quote · STALE: the feed has not advanced this name
Last $40.17Day +0.00%Mkt cap $722MP/E (FY) 27.5×1Y +57.7%Off 52W high −11.1%Vol (1Y) 52.5%
Daily closing price, split-adjusted to the current basis; 3y shown of 5,287 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest5.1% of sh out |
| Days to cover5.0d |
| 13F net flow (QoQ)+3.81% |
| Top-10 13F concentration84.1% |
| Next report (est.)2026-08-11 |
Short interest is FINRA semi-monthly, settlement 2026-06-30. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)27.5× |
| Sales (TTM)$48.6M |
| Earnings (TTM)$33.8M |
| ROE43.5% |
| Net margin60.8% |
| ROIC12.0% |
| Debt / equity1.30× |
| Sales growth 3Y105.3% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+51.1% |
| 1Y+57.7% |
| 3Y+148.7% |
| 5Y+22.2% |
| 10Y+258.7% |
| Since incept. (ann.)−11.6% |
Total return through 2026-07-21 · series begins 2005-07-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)52.5% |
| Ann. volatility (3Y)53.3% |
| Sharpe (1Y)1.15 |
| Sharpe (3Y)0.84 |
| Max drawdown (1Y)−42.4% |
| Max drawdown (3Y)−44.6% |
| Beta (3Y vs SPY)0.52 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BVF INC/IL | 2.6M | $81M | 14.40% | +0.0% |
| MORGAN STANLEY | 1.7M | $53M | 9.47% | −0.7% |
| FMR LLC | 1.3M | $41M | 7.25% | +12.1% |
| BlackRock, Inc. | 646,914 | $20M | 3.60% | +5.8% |
| Woodline Partners LP | 640,001 | $20M | 3.56% | +143.4% |
| VANGUARD CAPITAL MANAGEMENT LLC | 549,796 | $17M | 3.06% | new |
| Opaleye Management Inc. | 300,000 | $9M | 1.67% | +2.5% |
| GW&K Investment Management, LLC | 232,141 | $7M | 1.29% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-12 | $0.17 | +183.3% | $12.3M | −22.6% |
| 2025-12-31 | 2026-03-18 | — | — | $13.8M | +57.9% |
| 2025-09-30 | 2025-11-12 | $0.70 | — | $9.4M | +29.9% |
| 2025-06-30 | 2025-08-13 | $0.44 | −47.6% | $13.1M | +18.4% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-11 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Single Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
